Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextranomer + hyaluronic acid is a biocompatible injectable bulking agent consisting of dextranomer microspheres (80–250 μm) suspended in a stabilized non-animal hyaluronic acid (NASHA) gel. It is primarily indicated for the endoscopic treatment of vesicoureteral reflux (VUR) in children and fecal incontinence in adults. The hyaluronic acid gel acts as a temporary carrier that is absorbed within weeks, while the dextranomer microspheres remain at the injection site to stimulate fibroblast migration and collagen deposition. This process creates a durable, long-term tissue augmentation effect that provides a physical barrier to prevent urine backflow in VUR or augments bowel control in fecal incontinence. The product is marketed under the brand names Deflux for urological indications and Solesta for gastroenterological indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextranomer + hyaluronic acid.